At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 614 enrolled
Drug / intervention
9vHPV Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscular Recombinant 9-Valent Human Papillomavirus (9vHPV) Vaccine in Subjects Aged ≥9 to <15 Years in an Endemic Country for Dengue
In Brief
A Phase 3 clinical trial evaluating 9vHPV Vaccine and Dengue Tetravalent Vaccine (TDV) for Dengue Fever. Completed, enrolled 614 participants across 4 sites.
Detailed Summary
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue Fever
CountriesThailand
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartMay 2021
Primary CompletionFeb 2022
Study CompletionJul 2022
TodayJul 2026
First PostedMar 18, 2020
Enrollment StartMay 15, 2021
Primary CompletionFeb 21, 2022
Study CompletionJul 19, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.3 years ago
Interventions
9vHPV Vaccinebiological
9vHPV intramuscular injection
Dengue Tetravalent Vaccine (TDV)biological
TDV subcutaneous injection